Cystic & hereditary kidney disease
3 trials- 2020EARLY-PRO-TECTAlport syndromeIn 80 children with Alport syndrome, early ramipril delayed progression of albuminuria compared with placebo.
- 2017REPRISEADPKDIn 1,370 patients with later-stage ADPKD, tolvaptan slowed eGFR decline compared with placebo.
- 2012TEMPO 3:4ADPKDIn 1,445 patients with autosomal dominant polycystic kidney disease, tolvaptan slowed total kidney-volume growth compared with placebo.